Gregory Riely
@rielymd.bsky.social
Medical Oncologist in NYC. Ning Zhao and Ge Li Endowed Chair. Lung and thymic cancer. COI: https://coi.asco.org/share/EXW-L4KS/Gregory%20Riely
Editorial in @jama.com : jamanetwork.com/journals/jam... @sequistud.bsky.social
Letter with data: jamanetwork.com/journals/jam...
Letter with data: jamanetwork.com/journals/jam...
November 20, 2025 at 2:04 PM
Editorial in @jama.com : jamanetwork.com/journals/jam... @sequistud.bsky.social
Letter with data: jamanetwork.com/journals/jam...
Letter with data: jamanetwork.com/journals/jam...
Nice to see online from
@kcarbourmd.bsky.social @jessieross.bsky.social
and colleagues. Shows overlap of MTAP del and EGFR mut at baseline and resistance. Evidence of potential treatment option
www.jto.org/article/S155...
@mskcancercenter.bsky.social @iaslc.bsky.social @jtoonline.bsky.social
@kcarbourmd.bsky.social @jessieross.bsky.social
and colleagues. Shows overlap of MTAP del and EGFR mut at baseline and resistance. Evidence of potential treatment option
www.jto.org/article/S155...
@mskcancercenter.bsky.social @iaslc.bsky.social @jtoonline.bsky.social
November 17, 2025 at 9:08 PM
Nice to see online from
@kcarbourmd.bsky.social @jessieross.bsky.social
and colleagues. Shows overlap of MTAP del and EGFR mut at baseline and resistance. Evidence of potential treatment option
www.jto.org/article/S155...
@mskcancercenter.bsky.social @iaslc.bsky.social @jtoonline.bsky.social
@kcarbourmd.bsky.social @jessieross.bsky.social
and colleagues. Shows overlap of MTAP del and EGFR mut at baseline and resistance. Evidence of potential treatment option
www.jto.org/article/S155...
@mskcancercenter.bsky.social @iaslc.bsky.social @jtoonline.bsky.social
At New York Lung, Charlie Rudin @mskdeptofmed.bsky.social showing trials and investigators representing future approaches in small cell lung cancer @jessieross.bsky.social
November 15, 2025 at 3:51 PM
At New York Lung, Charlie Rudin @mskdeptofmed.bsky.social showing trials and investigators representing future approaches in small cell lung cancer @jessieross.bsky.social
This Congress will be in session tomorrow. Join us live or online! Great speakers with a multidisciplinary agenda. web.cvent.com/event/35cf07...
November 7, 2025 at 12:35 AM
This Congress will be in session tomorrow. Join us live or online! Great speakers with a multidisciplinary agenda. web.cvent.com/event/35cf07...
This figure from review article by Jordi Remon, Maurice Perol, et al. nicely shows the variety of approaches being studied in patients with stage III lung cancer. @natrevclinonc.nature.com www.nature.com/articles/s41...
October 9, 2025 at 12:00 PM
This figure from review article by Jordi Remon, Maurice Perol, et al. nicely shows the variety of approaches being studied in patients with stage III lung cancer. @natrevclinonc.nature.com www.nature.com/articles/s41...
a useful new paper on initial therapy of BRAF mut lung cancer. Retrospective data, but important question.
urldefense.com/v3/__https:/...
resulting from collaboration among 17 institutions including @mskcancercenter.bsky.social @danafarber.bsky.social @mdanderson.bsky.social
urldefense.com/v3/__https:/...
resulting from collaboration among 17 institutions including @mskcancercenter.bsky.social @danafarber.bsky.social @mdanderson.bsky.social
October 1, 2025 at 1:51 PM
a useful new paper on initial therapy of BRAF mut lung cancer. Retrospective data, but important question.
urldefense.com/v3/__https:/...
resulting from collaboration among 17 institutions including @mskcancercenter.bsky.social @danafarber.bsky.social @mdanderson.bsky.social
urldefense.com/v3/__https:/...
resulting from collaboration among 17 institutions including @mskcancercenter.bsky.social @danafarber.bsky.social @mdanderson.bsky.social
Important paper rebutting prior findings. "Thymectomy in adults with small or localized thymomas was not associated with increased 5-year mortality or cancer death." from @yalecancer.bsky.social in @iaslc.bsky.social JTO www.jto.org/article/S155...
September 24, 2025 at 4:27 PM
Important paper rebutting prior findings. "Thymectomy in adults with small or localized thymomas was not associated with increased 5-year mortality or cancer death." from @yalecancer.bsky.social in @iaslc.bsky.social JTO www.jto.org/article/S155...
nice review covering the topic of synthetic lethal approaches to cancer therapeutics in @natrevdrugdiscov.nature.com rdcu.be/eHDAK
September 22, 2025 at 9:36 PM
nice review covering the topic of synthetic lethal approaches to cancer therapeutics in @natrevdrugdiscov.nature.com rdcu.be/eHDAK
Fun debate between @stephenvliu.bsky.social and Mara Antonoff on value of social medicine in oncology today. #WCLC2025
September 6, 2025 at 11:30 AM
Fun debate between @stephenvliu.bsky.social and Mara Antonoff on value of social medicine in oncology today. #WCLC2025
June 2, 2025 at 1:22 PM
Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
June 1, 2025 at 2:19 PM
Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Excellent presentation at #ASCO25 on zipalertinib for patients with EGFR exon 20 NSCLC by Helena Yu @mskdeptofmed.bsky.social
June 1, 2025 at 2:09 PM
Excellent presentation at #ASCO25 on zipalertinib for patients with EGFR exon 20 NSCLC by Helena Yu @mskdeptofmed.bsky.social
@benlevylungdoc.bsky.social from Johns Hopkins reports results of chemo+datoDXD with biomarker data #ASCO25
June 1, 2025 at 1:25 PM
@benlevylungdoc.bsky.social from Johns Hopkins reports results of chemo+datoDXD with biomarker data #ASCO25
In discussion section at #ASCO25 Dr Rotow reminds that biopsy at progression remains important to understand and potentially target mechanisms of resistance to EGFR targeted therapy
May 31, 2025 at 1:57 PM
In discussion section at #ASCO25 Dr Rotow reminds that biopsy at progression remains important to understand and potentially target mechanisms of resistance to EGFR targeted therapy
Dr Cortellini argues for combination therapies as first in EGFR mut NSCLC
-benefits even occur in patients without factors identifying high risk disease
-high risk factors are common
-patients often don't make it to 2nd treatment
-combo tox improves over time #ASCO25
-benefits even occur in patients without factors identifying high risk disease
-high risk factors are common
-patients often don't make it to 2nd treatment
-combo tox improves over time #ASCO25
May 31, 2025 at 1:44 PM
Dr Cortellini argues for combination therapies as first in EGFR mut NSCLC
-benefits even occur in patients without factors identifying high risk disease
-high risk factors are common
-patients often don't make it to 2nd treatment
-combo tox improves over time #ASCO25
-benefits even occur in patients without factors identifying high risk disease
-high risk factors are common
-patients often don't make it to 2nd treatment
-combo tox improves over time #ASCO25
Good slide by Dr Rotow from @danafarber.bsky.social comparing financial and time toxicity of first line therapy options for EGFR mut NSCLC #ASCO25
May 31, 2025 at 1:37 PM
Good slide by Dr Rotow from @danafarber.bsky.social comparing financial and time toxicity of first line therapy options for EGFR mut NSCLC #ASCO25
Presentation by Dr Rotow from @danafarber.bsky.social advocating for single-agent osimertinib as standard for EGFR mut NSCLC.
- less benefit of combos for low risk disease
- not that much benefit for combo for some high risk features
- other options (consolidative RT and second line therapies)
- less benefit of combos for low risk disease
- not that much benefit for combo for some high risk features
- other options (consolidative RT and second line therapies)
May 31, 2025 at 1:35 PM
Presentation by Dr Rotow from @danafarber.bsky.social advocating for single-agent osimertinib as standard for EGFR mut NSCLC.
- less benefit of combos for low risk disease
- not that much benefit for combo for some high risk features
- other options (consolidative RT and second line therapies)
- less benefit of combos for low risk disease
- not that much benefit for combo for some high risk features
- other options (consolidative RT and second line therapies)
Great presentation by Dr Bauman at #ASCO25 highlights that there are many ways patients make decisions, with different priorities for their care.
May 31, 2025 at 1:15 PM
Great presentation by Dr Bauman at #ASCO25 highlights that there are many ways patients make decisions, with different priorities for their care.
Insightful discussion of targeting HER3 by @lilliansiu.bsky.social at #ASCO25
May 30, 2025 at 8:43 PM
Insightful discussion of targeting HER3 by @lilliansiu.bsky.social at #ASCO25
Data on iza-bren (BL-B01D1) an EGFR/HER3 ADC in patients with Small Cell and NSCLC (a variety of driver alterations). Fair response rate in all types of lung cancer (conf RR 48% in small cell) #ASCO25
May 30, 2025 at 8:19 PM
Data on iza-bren (BL-B01D1) an EGFR/HER3 ADC in patients with Small Cell and NSCLC (a variety of driver alterations). Fair response rate in all types of lung cancer (conf RR 48% in small cell) #ASCO25
Interesting data on DB-1310 a new HER3 ADC, presented by Lisberg with good responses in all solid tumors as well as EGFR mut lung #ASCO25 (just after Merck pulled their BLA for patritumab, another HER3 ADC in EGFR mut lung)
May 30, 2025 at 8:00 PM
Interesting data on DB-1310 a new HER3 ADC, presented by Lisberg with good responses in all solid tumors as well as EGFR mut lung #ASCO25 (just after Merck pulled their BLA for patritumab, another HER3 ADC in EGFR mut lung)
Congratulations to Saad Usmani on his Giant of Cancer Care award from @onclive.bsky.social at #ASCO25 @mskdeptofmed.bsky.social @szusmani.bsky.social
May 30, 2025 at 1:50 AM
Congratulations to Saad Usmani on his Giant of Cancer Care award from @onclive.bsky.social at #ASCO25 @mskdeptofmed.bsky.social @szusmani.bsky.social
Congratulations to my colleague Mark Kris on his Giant of Cancer Care award from @onclive.bsky.social at #ASCO25 @mskdeptofmed.bsky.social
May 30, 2025 at 1:48 AM
Congratulations to my colleague Mark Kris on his Giant of Cancer Care award from @onclive.bsky.social at #ASCO25 @mskdeptofmed.bsky.social